TransMedics Group Income Statement 2025-2011 | TMDX

Brief overview of profit and loss at TransMedics Group

This overview is based on financial performance over the past five years. TransMedics Group reported revenue of $25.6 million in 2020 and $605 million by 2025. The cumulative result was +2261.6%, corresponding to roughly 88.2% per year. Sales grew at a rate typical of a strong expansion phase.

Gross profit changed from 16.6 million dollars to 363 million dollars (+2081%). Direct costs outpaced revenue, limiting the benefit of changes in sales. Gross margin moved from 64.9% to 59.9%. A lower margin indicates deterioration in the economics of the core business.

EBITDA was −$24.8 million at the beginning and $136 million at the end of the period (+647.3%). Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from −96.8% to 22.4%. The business generated more EBITDA from each unit of revenue.

The final result was −$28.7 million initially and $190 million in the final year. The business moved out of a loss and ended the period with a profit.

The five-year change in capitalization reached +733.9%: from $563 million to $4.7 billion. The share-price trend was broadly consistent with improving results.

Conclusion

The figures do not all move in the same direction. The positive side is supported by improving net profitability, sales growth and higher operating efficiency. The most visible risks are a lower gross margin. Investors should continue to monitor margins, costs, and earnings quality.